Year: 2026
Type: article
Abstract: Type 1 autoimmune pancreatitis (AIP) is the pancreatic manifestation of IgG4-related disease. Glucocorticoids induce remission but relapse is common and toxicity limits maintenance use. Conventional immunosuppressants have a modest steroid-sparing role when B-cell therapy is unavailable. Rituximab is effective but off-label. Inebilizumab, a CD19-depleting antibody, is FDA-approved for adult IgG4-RD after MITIGATE showed an 87% reduction in adjudicated flares. Obexelimab, a nondepleting CD19/FcγRIIb inhibitor, reduced flare risk and glucocorticoid exposure in INDIGO; a BLA is under review. BTK inhibitors, FcRn blockade, and cellular therapies remain investigational. Treatment should be guided by organ burden, relapse risk, and comorbidity rather than a default steroid course for every patient.
DOI: 10.69734/8p34ma30
Authors: Yasmin Hernandez-Barco, Cory A. Perugino
Institutions: Harvard University, Massachusetts General Hospital
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W7214049177
